Next Article in Journal
Detection, Isolation and Characterization of Principal Synthetic Route Indicative Impurities in Verapamil Hydrochloride
Previous Article in Journal
Validated RP-HPLC Method for Simultaneous Quantitation of Losartan Potassium and Metolazone in Bulk Drug and Formulation
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications

by
Miroslav RADENKOVIĆ
Department of Pharmacology, Clinical Pharmacology and Toxicology; Faculty of Medicine; University of Belgrade; PO Box 38; 11129 Belgrade; Serbia
Sci. Pharm. 2014, 82(4), 709-722; https://doi.org/10.3797/scipharm.1407-16
Submission received: 22 July 2014 / Accepted: 18 August 2014 / Published: 18 August 2014

Abstract

The vascular endothelium has a central role in the modulation of vascular tone with associated antioxidant, anti-inflammatory, pro-fibrinolytic, anti-adhesive, and anticoagulant effects. This is primarily accomplished by the timely release of endothelial autacoids. On the other hand, endothelial dysfunction (ED) pro-voked by insulin resistance has been linked with reduced nitric oxide bioavailability, increased production of reactive oxygen species, and alterations of endothelial regeneration. Pioglitazone is classified as an insulin-sensitizing, anti-hyperglycemic agent. The mechanism of action associated with pio-glitazone includes the activation of peroxisome proliferator-activated receptor-gamma with stable improvement in glycemic control in diabetic patients. Today, it is known that apart from the beneficial effects on glucose homeostasis, pioglitazone exerts several pleiotropic effects, including the improvement of ED. Thus, the aim of this article was to summarize the current knowledge related to signaling mechanisms of the pioglitazone-induced improvement or reversal of ED. The relevant clinical studies and possible therapeutic implications connected to pioglitazone-related action on the endothelium were analyzed too.
Keywords: Pioglitazone; Endothelial dysfunction; Diabetes; Nitric oxide; PPARγ Pioglitazone; Endothelial dysfunction; Diabetes; Nitric oxide; PPARγ

Share and Cite

MDPI and ACS Style

RADENKOVIĆ, M. Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications. Sci. Pharm. 2014, 82, 709-722. https://doi.org/10.3797/scipharm.1407-16

AMA Style

RADENKOVIĆ M. Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications. Scientia Pharmaceutica. 2014; 82(4):709-722. https://doi.org/10.3797/scipharm.1407-16

Chicago/Turabian Style

RADENKOVIĆ, Miroslav. 2014. "Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications" Scientia Pharmaceutica 82, no. 4: 709-722. https://doi.org/10.3797/scipharm.1407-16

APA Style

RADENKOVIĆ, M. (2014). Pioglitazone and Endothelial Dysfunction: Pleiotropic Effects and Possible Therapeutic Implications. Scientia Pharmaceutica, 82(4), 709-722. https://doi.org/10.3797/scipharm.1407-16

Article Metrics

Back to TopTop